News

Alexion, AstraZeneca Rare Disease signed off on a letter of intent in Canada that brings Ultomiris (ravulizumab) — approved in the country for certain people with atypical hemolytic uremic syndrome (aHUS) — a step closer to becoming available under public drug plans. The letter, to the pan-Canadian Pharmaceutical…

Both Soliris (eculizumab) and Ultomiris (ravulizumab) are safe, and have similar effectiveness in improving kidney function and blood parameters in people with atypical hemolytic syndrome (aHUS), according to a new systematic review study. However, Ultomoris “was preferred by a majority of the patients as it only has…

Complement-blocking medications like Soliris (eculizumab) can be effective for controlling atypical hemolytic uremic syndrome (aHUS) in patients carrying a genetic variant called the MCPggaac haplotype, a new study reports. Researchers in Southeastern Europe reviewed the cases of 14 children in the region with aHUS to determine the best…

Blood concentrations of Soliris (eculizumab) needed to fully suppress the immune complement cascade may be higher than previously thought in people with atypical hemolytic uremic syndrome (aHUS), according to a study from Spain. Most patients were found to have concentrations above estimated therapeutic levels in their bloodstream before…

A group of blood disorders called hypereosinophilia syndrome, known as HES, was suspected to be the trigger event that led to atypical hemolytic uremic syndrome (aHUS) in a woman in her late 30s, according to a new case study. HES is caused by an overload of eosinophils, a type…

With the theme “Capabilities and Possibilities,” this year’s aHUS Awareness Day — observed annually on Sep. 24 — seeks to highlight the achievements and aspirations of those living with atypical hemolytic uremic syndrome (aHUS). Overarchingly, the annual global event aims to call attention to aHUS itself, to educate…

Getting vaccinated against COVID-19 may protect people with atypical hemolytic uremic syndrome (aHUS) from the infection’s severe complications, without raising major safety issues, a small study finds. Receiving a double booster shot may be important to provide full protection, especially for transplant patients. “Our findings support the use of COVID-19…

Mutations in the THBD gene — previously suggested to predispose people to atypical hemolytic uremic syndrome (aHUS) — might not make any significant contribution to the disease’s development and its severity, according to a small Spanish study. The mutations were found in Spanish aHUS patients at similar frequencies to…

Relapses were less likely in people with atypical hemolytic uremic syndrome (aHUS) treated with Soliris (eculizumab) after a kidney transplant, and they had better kidney function and a lower risk of transplant rejection, according to a meta-analysis of published studies. “This meta-analysis … demonstrated that [Soliris] produced meaningful…

The safety profile of Soliris (eculizumab) in real-world practice is similar to that reported in clinical trials, according to a large analysis of data from Japan. “This is the largest safety dataset on [Soliris] in Japan derived from more than 10 years of clinical experience,” the researchers wrote. “No…